Some Pediatric Patients With Wilms' Tumor Can Avoid Doxorubicin

the ONA take:

According to a new study published in the journal The Lancet, researchers have found that children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.

For the 10-year trial, researchers followed 583 pediatric patients with stage II or III Wilm's tumor who were at intermediate risk for disease relapse. Results demonstrated that 96.5% of patients whose treatment regimen contained doxorubicin survived for 5 or more years versus 95.8% of those who did not receive the cardiotoxic drug. Researchers found that those who did not receive doxorubicin and relapsed could be successfully re-treated.

"Thanks to the results of this trial fewer children with this disease will have to have treatment that could cause them lifelong side effects without much benefit," lead author Professor Kathy Pritchard-Jones, a researcher at the Institute of Child Health, University College London and consultant oncologist at Great Ormond Street Hospital in London said.

When caring for pediatric oncology patients, awareness of patients’ emotional needs is important.
Children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
Children with a rare type of cancer called Wilms' tumour who are at low risk of relapsing can now be given less intensive treatment, avoiding a type of chemotherapy that can cause irreversible heart problems in later life.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs